RXRX

+ Watchlist + Portfolio

Recursion Pharmaceuticals, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.07
52-Week Range: $2.77 – $7.18
Market Cap: $2.21B
P/E (TTM): —
EPS (TTM): -1.00
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.41
PEG Ratio: —
Return on Equity: -56.58%
Return on Assets: -27.33%
Gross Margin: 0.00%
Operating Margin: -1759.69%
Profit Margin: 0.00%
Current Ratio: 5.03
Debt/Equity: 0.07
Total Debt: $66.64M
Free Cash Flow: $-219.49M
Revenue Growth: -60.10%
Earnings Growth: —
Enterprise Value: $1.73B

RXRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$39.68M	$43.88M	$58.49M	$74.26M
Cost of Revenue	$48.27M	$42.59M	$45.24M	$70.95M
Gross Profit	-$8.59M	$1.29M	$13.25M	$3.30M
Research & Development	$155.70M	$241.23M	$314.42M	$475.27M
Selling, General & Admin	$81.60M	$110.82M	$178.18M	$176.59M
Operating Expenses	$237.13M	$351.35M	$492.25M	$651.43M
Operating Income	-$245.73M	-$350.06M	-$479.00M	-$648.13M
EBITDA	-$227.66M	-$307.63M	-$426.72M	-$559.38M
Pretax Income	-$239.48M	-$332.13M	-$464.79M	-$644.89M
Income Tax	$0.00	-$4.06M	-$1.13M	-$136.00K
Net Income	-$239.48M	-$328.07M	-$463.66M	-$644.76M
Diluted EPS	-1.36	-1.58	-1.69	-1.44
Diluted Shares	175.54M	207.85M	274.21M	447.45M

RXRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$549.91M	$391.56M	$594.35M	$743.29M
Receivables	$2.75M	$3.09M	$49.17M	$24.65M
Current Assets	$569.81M	$438.14M	$714.27M	$812.85M
Total Assets	$701.29M	$653.70M	$1.45B	$1.47B
Current Liabilities	$100.27M	$93.17M	$187.47M	$147.71M
Long-Term Debt	$536.00K	$1.10M	$19.02M	$9.56M
Total Debt	$51.01M	$50.67M	$108.49M	$77.97M
Total Liabilities	$215.48M	$190.26M	$413.82M	$343.26M
Retained Earnings	-$639.56M	-$967.62M	-$1.43B	-$2.08B
Shareholders' Equity	$485.81M	$463.44M	$1.03B	$1.13B
Working Capital	$469.55M	$344.97M	$526.80M	$665.14M

RXRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$83.52M	-$287.78M	-$359.17M	-$371.81M
Capital Expenditure	-$37.36M	-$12.55M	-$17.05M	-$8.63M
Free Cash Flow	-$120.88M	-$300.33M	-$376.22M	-$380.44M
Depreciation & Amortisation	$11.76M	$24.40M	$36.49M	$83.70M
Stock-Based Compensation	$27.91M	$53.50M	$81.69M	$111.22M
Investing Cash Flow	$193.25M	-$10.23M	$260.06M	-$16.87M
Financing Cash Flow	$154.34M	$140.13M	$304.12M	$521.53M
Net Change in Cash	$264.07M	-$157.88M	$205.00M	$132.85M

RXRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$14.82M	$19.10M	$4.98M	$35.35M	$6.30M	$7.30M
Cost of Revenue	$21.83M	$20.16M	$14.69M	$14.28M	$12.49M	$11.49M
Gross Profit	-$7.01M	-$1.06M	-$9.70M	$21.08M	-$6.19M	-$4.19M
Research & Development	$129.63M	$128.64M	$121.06M	$95.94M	$87.90M	$89.61M
Selling, General & Admin	$54.65M	$46.65M	$41.63M	$33.66M	$34.59M	$41.53M
Operating Expenses	$184.36M	$175.17M	$162.50M	$129.41M	$122.32M	$130.78M
Operating Income	-$191.37M	-$176.23M	-$172.20M	-$108.33M	-$128.50M	-$134.97M
EBITDA	-$182.81M	-$147.57M	-$140.37M	-$88.63M	-$102.08M	-$112.53M
Pretax Income	-$202.65M	-$171.90M	-$162.25M	-$108.10M	-$122.11M	-$131.01M
Income Tax	-$158.00K	$0.00	$3.00K	$20.00K	-$4.60M	-$1.00K
Net Income	-$202.49M	-$171.90M	-$162.25M	-$108.12M	-$117.50M	-$131.00M
Diluted EPS	-0.50	-0.41	-0.36	-0.21	-0.22	-0.25
Diluted Shares	402.77M	417.36M	446.99M	526.72M	529.30M	532.46M

RXRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$500.45M	$525.11M	$659.84M	$743.29M	$654.47M	$545.68M
Receivables	$46.12M	$21.61M	$21.91M	$24.65M	$13.59M	$14.39M
Current Assets	$584.14M	$587.16M	$714.11M	$812.85M	$709.56M	$603.46M
Total Assets	$1.31B	$1.30B	$1.40B	$1.47B	$1.34B	$1.21B
Current Liabilities	$141.98M	$164.03M	$155.10M	$147.71M	$129.70M	$119.89M
Long-Term Debt	$16.45M	$14.20M	$11.90M	$9.56M	$7.18M	$4.75M
Total Debt	$92.91M	$88.08M	$82.37M	$77.97M	$72.38M	$66.64M
Total Liabilities	$371.29M	$383.21M	$352.58M	$343.26M	$314.75M	$297.67M
Retained Earnings	-$1.63B	-$1.81B	-$1.97B	-$2.08B	-$2.19B	-$2.32B
Shareholders' Equity	$933.95M	$919.15M	$1.05B	$1.13B	$1.02B	$915.00M
Working Capital	$442.16M	$423.13M	$559.00M	$665.14M	$579.86M	$483.58M

RXRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$131.96M	-$76.42M	-$117.36M	-$46.07M	-$81.10M	-$105.95M
Capital Expenditure	-$1.83M	-$5.31M	-$243.00K	-$1.24M	-$338.00K	-$1.96M
Free Cash Flow	-$133.79M	-$81.73M	-$117.60M	-$47.32M	-$81.44M	-$107.91M
Depreciation & Amortisation	$19.33M	$23.85M	$21.04M	$19.48M	$19.67M	$18.17M
Stock-Based Compensation	$36.06M	$26.16M	$25.24M	$23.76M	$22.21M	$19.50M
Investing Cash Flow	-$7.27M	-$5.81M	-$2.55M	-$1.24M	-$338.00K	-$1.96M
Financing Cash Flow	$40.53M	$97.66M	$251.34M	$132.01M	-$3.47M	-$1.27M
Net Change in Cash	-$98.70M	$15.43M	$131.43M	$84.69M	-$84.91M	-$109.17M

Market Snapshot

About

Recursion Pharmaceuticals, Inc. is a biotechnology company pioneering the use of artificial intelligence and machine learning in drug discovery. The company operates a massive biological and chemical dataset to identify new therapeutic candidates across multiple disease areas. Recursion combines experimental biology, automation, and computational power to industrialize drug discovery at scale.